Merck has announced the acquisition of Verona Pharma for 10 billion dollars, strengthening its portfolio of respiratory treatments.
Raluca Ioana Draghici
.webp)
Economy
www.shutterstock.com
Always see our news on Google
Pharmaceutical giant Merck has decided to acquire the British company Verona Pharma for about 10 billion dollars, paying 107 dollars per share, a 23% premium. The strategic move comes amid Merck's desire to diversify its revenue streams, given that the patent for its Keytruda oncology treatment will expire in 2028. This is a continuation of Merck's efforts to expand its portfolio, given previous acquisitions including Prometheus Biosciences.
Sources
Latest News
15:04
The prefect of Covasna County has been sent to trial by the DNA.
15:02
Mayor Mihai Chirica responded to critics regarding the stopping of street lighting at night, emphasizing the need for energy rationalization.
14:58
A 17-year-old girl from Covasna has been placed in preventive detention for 30 days after attacking a police officer during an intervention.
14:58
ANI reported that 35% of active prohibitions are related to conflicts of interest, the majority of the targeted individuals holding elective positions.
14:54
Oana Gheorghiu accuses a coordinated attack on her Facebook account: "My Facebook profile was attacked by a network of 3,500 fake accounts"
See more news
NEWS ON THE SAME TOPICS
International
AstraZeneca, negotiations with Bristol Myers Squibb for a possible merger that could create a 400 billion dollar group
International
Alphabet announces the sale of shares up to 80 billion dollars to finance the development of artificial intelligence
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
